Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences ...

Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating obesity and the resulting ...

Management will be in attendance to participate in one-on-one and group meetings during each event. Interested investors should contact their Wells Fargo and Stifel representatives, respectively, to ...

AURORA, Colo., Oct. 1, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human ...

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Second oral presentation will provide updated data from GDFATHER-01 trial demonstrating deep and durable remissions in heavily pretreated patients CatalYm, a world-leader in neutralizing GDF-15 in ...

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced two upcoming oral presentations highlighting the company’s ...

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster ...

The American South is brimming with boundary-pushing talent, but these five wavemakers are reshaping the region’s visual ...

A sort of "lkala 2.0", snus is a flavored pouch of tobacco that has mass appeal to young people. Presented as an alternative ...